Publications by authors named "Ashley Matusz-Fisher"
Article Synopsis
- - Venetoclax is an effective treatment for chronic lymphocytic leukemia (CLL) that can lead to long-lasting remissions but carries a risk of tumor lysis syndrome (TLS), which necessitates careful monitoring during treatment.
- - A study at Levine Cancer Institute examined 73 patients with CLL on venetoclax to determine how often TLS monitoring led to interventions, finding that strict adherence to monitoring occurred in 66% of cases.
- - Results showed a low incidence of TLS, with only one laboratory case reported and no clinical cases, indicating that most patients, especially those with low tumor burden, required few interventions.
Article Synopsis
- HER2-positive breast cancers make up about 15-20% of all breast cancer cases and historically have a worse prognosis, but the use of HER2-targeted treatments has improved patient outcomes.
- Despite these advancements, around 20% of patients still experience relapses, highlighting the need for new treatment strategies, particularly in immunotherapy.
- Current clinical trials are investigating immune checkpoint inhibitors, like pembrolizumab and nivolumab, in combination with HER2-targeted therapies, showing promise in treating HER2-positive breast cancer, especially in tumors positive for PD-L1.
Background: We evaluated time to thromboembolism (TE) and risk factors in multiple myeloma (MM) patients after first exposure to immunomodulatory therapy, stratified by thromboprophylaxis.
Patients And Methods: We retrospectively analyzed adult MM patients who received immunomodulatory therapy with or without dexamethasone between February 2012 and October 2017. Thromboprophylaxis included aspirin, anticoagulants (low-molecular-weight heparin, direct oral anticoagulants, or warfarin), or none.